Abhishek Singhal

Jump to

SRL likely to be valued 25 times FY18 operating profit:Macquarie

Singhal sees significant opportunity for diagnositics players such as Dr Lal Path Labs, Thyrocare and SRL. Organised players are already gaining market share and companies which maintain quality standards will definitely do well, he says.
Lupin to see approvals after US FDA gives clean chit: Macquarie

Of the total 18 observations, 9 from July 2015 and another 9 from March 2016 inspection, the former ones relating to equipment and warehousing have been closed. Nine observations are still outstanding for the company.
Glenmark Pharma a top pick in pharma space: Macquarie

In an exclusive interview with CNBC TV-18's Udayan Mukherjee and Mitali Mukherjee, Abhishek Singhal of Macquarie, said that Glenmark would be his top pick in the Indian pharma space since sentiment is positive for the pharma firm after its pact with pharma major Sanofi.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Abhishek Singhal

SRL likely to be valued 25 times FY18 operating profit:Macquarie

Lupin to see approvals after US FDA gives clean chit: Macquarie

Glenmark Pharma a top pick in pharma space: Macquarie